Correction to: Recent advances in Surface Guided Radiation Therapy.

An amendment to this paper has been published and can be accessed via the original article.

Recent advanced in Surface Guided Radiation Therapy.

The growing acceptance and recognition of Surface Guided Radiation Therapy (SGRT) as a promising imaging technique has supported its recent spread in a large number of radiation oncology facilities. Although this technology is not new, many aspects of it have only recently been exploited. This review focuses on the latest SGRT developments, both in the field of general clinical applications and special techniques.SGRT has a wide range of applications, including patient positioning with real-time feedback, patient monitoring throughout the treatment fraction, and motion management (as beam-gating in free-breathing or deep-inspiration breath-hold). Special radiotherapy modalities such as accelerated partial breast irradiation, particle radiotherapy, and pediatrics are the most recent SGRT developments.The fact that SGRT is nowadays used at various body sites has resulted in the need to adapt SGRT workflows to each body site. Current SGRT applications range from traditional breast irradiation, to thoracic, abdominal, or pelvic tumor sites, and include intracranial localizations.Following the latest SGRT applications and their specifications/requirements, a stricter quality assurance program needs to be ensured. Recent publications highlight the need to adapt quality assurance to the radiotherapy equipment type, SGRT technology, anatomic treatment sites, and clinical workflows, which results in a complex and extensive set of tests.Moreover, this review gives an outlook on the leading research trends. In particular, the potential to use deformable surfaces as motion surrogates, to use SGRT to detect anatomical variations along the treatment course, and to help in the establishment of personalized patient treatment (optimized margins and motion management strategies) are increasingly important research topics. SGRT is also emerging in the field of patient safety and integrates measures to reduce common radiotherapeutic risk events (e.g. facial and treatment accessories recognition).This review covers the latest clinical practices of SGRT and provides an outlook on potential applications of this imaging technique. It is intended to provide guidance for new users during the implementation, while triggering experienced users to further explore SGRT applications.

A gEUD-based inverse planning technique for HDR prostate brachytherapy: feasibility study.

PURPOSE: The purpose of this work was to study the feasibility of a new inverse planning technique based on the generalized equivalent uniform dose for image-guided high dose rate (HDR) prostate cancer brachytherapy in comparison to conventional dose-volume based optimization. METHODS: The quality of 12 clinical HDR brachytherapy implants for prostate utilizing HIPO (Hybrid Inverse Planning Optimization) is compared with alternative plans, which were produced through inverse planning using the generalized equivalent uniform dose (gEUD). All the common dose-volume indices for the prostate and the organs at risk were considered together with radiobiological measures. The clinical effectiveness of the different dose distributions was investigated by comparing dose volume histogram and gEUD evaluators. RESULTS: Our results demonstrate the feasibility of gEUD-based inverse planning in HDR brachytherapy implants for prostate. A statistically significant decrease in D10 or/and final gEUD values for the organs at risk (urethra, bladder, and rectum) was found while improving dose homogeneity or dose conformity of the target volume. CONCLUSIONS: Following the promising results of gEUD-based optimization in intensity modulated radiation therapy treatment optimization, as reported in the literature, the implementation of a similar model in HDR brachytherapy treatment plan optimization is suggested by this study. The potential of improved sparing of organs at risk was shown for various gEUD-based optimization parameter protocols, which indicates the ability of this method to adapt to the user's preferences.

SU-E-T-495: Monte Carlo Dose Verification of Passive Scattering Proton Therapy for Prostate Cancer.

PURPOSE: To verify the clinical pencil beam dose calculation algorithm for passive scattering proton therapy using field with large range in tissue, i.e. in prostate cancer, using a Monte Carlo (MC) simulation system. METHODS: Previously treated prostate cancer cases were randomly selected from our patient database. All patients received the same dose prescription of 50Gy (25 fractions) to planning treatment volume including the seminal vesicles (PTV1), followed by 28Gy (14 fractions) boost to the prostate gland only (PTV2). Patient and beam geometry were imported to our MC simulation platform (TOPAS - TOol for PArticle Simulation) and the dose of each individual beam, as well as their weighted sum, were calculated and compared to pencil beam algorithm-based calculation from the clinical treatment planning system (XiO). RESULTS: Preliminary results from four patient cases show overall good agreement between the pencil beam and MC calculations. However, a small but systematic overestimation of the dose, as calculated by the pencil beam calculation algorithm, was noticed for the target structures (<2% difference in D95 for PTV1 and PTV2), compared to the MC calculation. The inverse was observed for the OARs (rectum and bladder) for which the dose seems to be somewhat underestimated by the pencil beam calculation algorithm (up to 3.75% difference in the volume covered by the 70Gy and 75Gy isodose lines). Furthermore, systematic difference in the range calculation was noticed: the pencil beam calculation algorithm results in larger proton range, in the order of 3-4mm, compared to the MC calculations for all beams and patients studied. This can be attributed to the bone anatomy in the path of the beams (femoral heads). CONCLUSIONS: Routine MC dose calculation has the potential to improve delivery accuracy in proton therapy of prostate cancer and influence the analysis of currently ongoing clinical trials of protons versus IMRT. Funded by NIH/NCI R01 CA140735.

SU-E-T-552: Maximizing the Biological Effect of Proton Dose Delivered with Scanned Beam.

PURPOSE: Biological effect of radiation can be enhanced with hypofractionation, localized dose escalation, and controlled distribution of proton's linear energy transfer (LET). We evaluate potential gain in therapeutic effect from delivery of daily inhomogeneous fractional dose distributions in pencil beam scanning proton therapy (PBS-PT). METHODS: For cases of prostate cancer, we considered a hypofractionated course of 20 fractions of 3 Gy (assuming α/ß=1.5, the equivalent dose in 2-Gy fractions (ED2Gy) is 77.1 Gy). Two sets of dose distributions were planned using two opposed lateral fields to deliver a uniform dose: (1) in full-target plans (FTP) each beam targeted the entire gland (2) in split-target plans (STP), beams targeted only the respective proximal hemispheres (prostate split sagittally). Linear combinations of optimized beam intensity maps from FTP and STP, for a variety of mixing weights, were used to evaluate inhomogeneous fractional dose (IFD) distributions. IFD delivered doses boosting either hemisphere in alternating fractions, e.g., alternating between 40% and 160% of the nominal fractional dose (1.2-4.8 Gy). The equivalent uniform dose (EUD) was calculated for ED2Gy distributions. IFD plans were rescaled so that the EUD of rectum and bladder did not increase. LET distributions were calculated with Monte Carlo, and compared for different plans. RESULTS: In the IFD courses, the whole prostate received a nearly uniform dose in every 2 fractions, however EUD was higher than in conventional FTP by up to 8%. Rectal EUD decreased by 2%, and bladder EUD was unchanged. The LET distributions of FTP and STP were distinctly different, thus, in IFD, LET depended strongly on the mixing weights. CONCLUSIONS: In PBS-PT, modestly improved therapeutic outcome can be expected with delivery of inhomogeneous daily dose distributions, while administering the prescribed dose to target over the entire course. The biological effectiveness may be further enhanced by optimizing the LET distributions. The project was supported by the Federal Share of program income earned by Massachusetts General Hospital on C06 CA059267, Proton Therapy Research and Treatment Center.

Radiobiological and dosimetric analysis of daily megavoltage CT registration on adaptive radiotherapy with Helical Tomotherapy.

Pre-treatment patient repositioning in highly conformal image-guided radiation therapy modalities is a prerequisite for reducing setup uncertainties. In Helical Tomotherapy (HT) treatment, a megavoltage CT (MVCT) image is usually acquired to evaluate daily changes in the patient's internal anatomy and setup position. This MVCT image is subsequently compared to the kilovoltage CT (kVCT) study that was used for dosimetric planning, by applying a registration process. This study aims at investigating the expected effect of patient setup correction using the Hi-Art tomotherapy system by employing radiobiological measures such as the biologically effective uniform dose (D) and the complication-free tumor control probability (P(+)). A new module of the Tomotherapy software (TomoTherapy, Inc, Madison, WI) called Planned Adaptive is employed in this study. In this process the delivered dose can be calculated by using the sinogram for each delivered fraction and the registered MVCT image set that corresponds to the patient's position and anatomical distribution for that fraction. In this study, patients treated for lung, pancreas and prostate carcinomas are evaluated by this method. For each cancer type, a Helical Tomotherapy plan was developed. In each cancer case, two dose distributions were calculated using the MVCT image sets before and after the patient setup correction. The fractional dose distributions were added and renormalized to the total number of fractions planned. The dosimetric and radiobiological differences of the dose distributions with and without patient setup correction were calculated. By using common statistical measures of the dose distributions and the P(+) and D concepts and plotting the tissue response probabilities vs. D a more comprehensive comparison was performed based on radiobiological measures. For the lung cancer case, at the clinically prescribed dose levels of the dose distributions, with and without patient setup correction, the complication-free tumor control probabilities, P(+) are 48.5% and 48.9% for a D(ITV) of 53.3 Gy. The respective total control probabilities, P(B) are 56.3% and 56.5%, whereas the corresponding total complication probabilities, P(I) are 7.9% and 7.5%. For the pancreas cancer case, at the prescribed dose levels of the two dose distributions, the P(+) values are 53.7% and 45.7% for a D(ITV) of 54.7 Gy and 53.8 Gy, respectively. The respective P(B) values are 53.7% and 45.8%, whereas the corresponding P(I) values are ~0.0% and 0.1%. For the prostate cancer case, at the prescribed dose levels of the two dose distributions, the P(+) values are 10.9% for a D(ITV) of 75.2 Gy and 11.9% for a D(ITV) of 75.4 Gy, respectively. The respective P(B) values are 14.5% and 15.3%, whereas the corresponding P(I) values are 3.6% and 3.4%. Our analysis showed that the very good daily patient setup and dose delivery were very close to the intended ones. With the exception of the pancreas cancer case, the deviations observed between the dose distributions with and without patient setup correction were within ±2% in terms of P(+). In the radiobiologically optimized dose distributions, the role of patient setup correction using MVCT images could appear to be more important than in the cases of dosimetrically optimized treatment plans were the individual tissue radiosensitivities are not precisely considered.

Monte Carlo Modeling and Commissioning of a Dual-layer Micro Multileaf Collimator.

The purpose of this study was to commission a first-of-its-kind dual-layer micro multileaf collimator (mMLC) system by using Monte Carlo dose calculations. The mMLC is attached on a Varian 600C linac. Having a lower and an upper layer of MLC leaves, this mMLC allows for field shaping in two orthogonal directions. The commissioning of the system was performed in two steps: without and with the mMLC attached on the linac. The treatment head without and with the mMLC was modeled in the BEAMnrc Monte Carlo (MC) code. The scoring planes for the phase space files were specified below the linac's secondary collimators (jaws) and above and below the mMLC. With the mMLC attached to the linac the field size was defined by the jaws as 10 x 10 cm(2), which is also the maximum possible field size that can be shaped by the mMLC. For the commissioning of the linac, several fields of various sizes were simulated and compared against ionization chamber measurements in a water phantom. Output factors for several field sizes, as well as percent depth dose curves and dose profiles for rectangular and irregular shape fields, were calculated and compared against measurements in water. Agreement between measured and calculated data was better than 1% and less than 1.0 mm in the penumbra region for open fields. With the mMLC attached, the agreement between measurements and MC calculations is within 1.0% or 1.0 mm in the penumbra region.